Avoro Capital Advisors OCUL Position
Active9-Fund ConvergenceAvoro Capital Advisors increased their position in Ocular Therapeutix Inc. (OCUL) in Q4 2025, holding $130.8M worth of shares across 10,777,777 shares.
The position was first reported in Q1 2024 and has been tracked across 8 quarterly 13F filings.
OCUL is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for OTX-TKI (axitinib implant) in 13 days (Apr 29, 2026), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 10.9% of float with 2.5 days to cover, indicating significant bearish positioning against Avoro Capital's long thesis.
About Ocular Therapeutix Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Full company profile →Short Interest
10.9%
2.5 days to cover
Avoro Capital Advisors OCUL Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 10,777,777 | +527,777 | $130.8M |
| Q3 2025 | Increased | 10,250,000 | +2,850,000 | $119.8M |
| Q2 2025 | Decreased | 7,400,000 | -660,000 | $68.7M |
| Q1 2025 | Held | 8,060,000 | — | $59.1M |
| Q4 2024 | Held | 8,060,000 | — | $68.8M |
| Q3 2024 | Held | 8,060,000 | — | $70.1M |
| Q2 2024 | Increased | 8,060,000 | +911,064 | $55.1M |
| Q1 2024 | New | 7,148,936 | +7,148,936 | $65.1M |
Frequently Asked Questions
Does Avoro Capital Advisors own OCUL?
Yes. As of Q4 2025, Avoro Capital Advisors holds 10,777,777 shares of Ocular Therapeutix Inc. (OCUL) valued at $130.8M. This data comes from their SEC 13F filing.
How many hedge funds own OCUL?
9 specialist biotech hedge funds currently hold OCUL, including Deep Track Capital, Perceptive Advisors, Eventide Asset Management and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy OCUL?
Avoro Capital Advisors's position in OCUL was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's OCUL position increasing or decreasing?
Avoro Capital Advisors increased their OCUL position in the most recent quarter, adding 527,777 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OCULCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →